This approach of direct C3 targeting in COVID‐19 is attractive, as it is aimed at blocking virus‐induced LP and CP activation as well as LP/CP‐driven activation of the amplification loop, at the bottleneck of all the pathways (Figure 1). The gene discussed is CP; the disease is COVID-19.